IL281729A - Low-intensity therapy with CPX-351 for hematologic disorders - Google Patents

Low-intensity therapy with CPX-351 for hematologic disorders

Info

Publication number
IL281729A
IL281729A IL281729A IL28172921A IL281729A IL 281729 A IL281729 A IL 281729A IL 281729 A IL281729 A IL 281729A IL 28172921 A IL28172921 A IL 28172921A IL 281729 A IL281729 A IL 281729A
Authority
IL
Israel
Prior art keywords
cpx
low intensity
hematological disorders
intensity treatment
treatment
Prior art date
Application number
IL281729A
Other languages
English (en)
Hebrew (he)
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of IL281729A publication Critical patent/IL281729A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL281729A 2018-09-25 2021-03-22 Low-intensity therapy with CPX-351 for hematologic disorders IL281729A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862736393P 2018-09-25 2018-09-25
US201862772372P 2018-11-28 2018-11-28
PCT/US2019/052952 WO2020068979A1 (en) 2018-09-25 2019-09-25 Low-intensity treatment of hematological disorders

Publications (1)

Publication Number Publication Date
IL281729A true IL281729A (en) 2021-05-31

Family

ID=69950910

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281729A IL281729A (en) 2018-09-25 2021-03-22 Low-intensity therapy with CPX-351 for hematologic disorders

Country Status (11)

Country Link
US (3) US20240252522A1 (cg-RX-API-DMAC10.html)
EP (1) EP3856198A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022502498A (cg-RX-API-DMAC10.html)
KR (1) KR20210065962A (cg-RX-API-DMAC10.html)
CN (1) CN113164502A (cg-RX-API-DMAC10.html)
AU (1) AU2019350759A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021005539A2 (cg-RX-API-DMAC10.html)
CA (1) CA3114002A1 (cg-RX-API-DMAC10.html)
IL (1) IL281729A (cg-RX-API-DMAC10.html)
MX (1) MX2021003527A (cg-RX-API-DMAC10.html)
WO (1) WO2020068979A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
US20240252522A1 (en) * 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
CA3216716A1 (en) 2021-05-03 2022-11-10 Tim BERGBREDE Composition comprising an inhibitor of mitochondrial transcription

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
EP1432403B1 (en) 2001-10-03 2010-07-28 Celator Pharmaceuticals, Inc. Liposome loading with metal ions
US20050118250A1 (en) 2001-11-13 2005-06-02 Paul Tardi Lipid carrier compositions with enhanced blood stability
JP4972545B2 (ja) 2004-04-22 2012-07-11 セレーター ファーマスーティカルズ、インク. アントラサイクリン系薬剤及びシチジンアナログのリポソーム製剤
PT2120568T (pt) 2007-02-16 2017-12-04 Celator Pharmaceuticals Inc Rácios de fármacos fixados para tratamento de cancros hematopoiéticos e desordens proliferativas
PT2768484T (pt) 2011-10-21 2019-10-28 Jazz Pharmaceuticals Res Llc Lipossomas liofilizados
BR112018009463A8 (pt) * 2015-11-11 2019-02-26 Celator Pharmaceuticals Inc ensaios e métodos para selecionar um regime de tratamento para um sujeito com leucemia
KR20230100748A (ko) * 2016-07-28 2023-07-05 노파르티스 아게 키메라 항원 수용체 및 pd-1 억제제의 조합 요법
CN110088166B (zh) 2016-12-01 2021-06-08 Jxtg能源株式会社 全芳香族液晶聚酯树脂
US20240252522A1 (en) * 2018-09-25 2024-08-01 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
US11980636B2 (en) * 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders

Also Published As

Publication number Publication date
CA3114002A1 (en) 2020-04-02
KR20210065962A (ko) 2021-06-04
AU2019350759A1 (en) 2021-04-22
US20210393665A1 (en) 2021-12-23
CN113164502A (zh) 2021-07-23
JP2022502498A (ja) 2022-01-11
BR112021005539A2 (pt) 2021-06-29
EP3856198A1 (en) 2021-08-04
EP3856198A4 (en) 2022-06-22
US20260014183A1 (en) 2026-01-15
US12370207B2 (en) 2025-07-29
US20240252522A1 (en) 2024-08-01
WO2020068979A1 (en) 2020-04-02
MX2021003527A (es) 2021-05-27

Similar Documents

Publication Publication Date Title
IL289650A (en) Azolopyrimidine for the treatment of cancer-related disorders
IL273693A (en) Treatment of inflammatory disorders
IL293783A (en) Compounds and compositions for treating hematological disorders
IL269302A (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
IL267229A (en) Methods of treating ocular disorders
IL270752B (en) Pyrrolopyridine-aniline compounds for the treatment of skin disorders
GB201804514D0 (en) Treatment of pyroptosis
IL258032B (en) Compounds and preparations for the treatment of ocular disorders
GB201608046D0 (en) Treatment of complement-mediated disorders
IL270781A (en) Treatment of depressive disorders
IL282643A (en) Soft combinations for the treatment of hematological diseases
IL314274A (en) Treatment of skin disorders
GB201607388D0 (en) Treatment of impulsivity-related disorders
GB201612043D0 (en) Composition for treatment of disorders
GB201804515D0 (en) Treatment of necroptosis
PT3458067T (pt) Tratamento de distúrbios neurológicos
ZA202002910B (en) Treatment of skin disorders
GB201907305D0 (en) Treatment of conditions
GB201604359D0 (en) Treatment of tissue disorders
SG11202007642RA (en) Treatment of disorders with tasimelteon
GB201917253D0 (en) Treatment of conditions
GB201812276D0 (en) Treatment of cognitive disorders
GB201809408D0 (en) Treatment of Cognitive Disorders
GB201801249D0 (en) Methods of treatment
GB201900942D0 (en) Methods of treatment